Posts tagged King's College London
Tech News: ViroCell Biologics
Tech News: ViroCell Biologics

ViroCell Biologics, the UK’s first clinical trial-focused viral vector manufacturer, has officially launched.

It aims to be the supplier of choice for viral vectors and gene-modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials.

Read More
In the NewsFlorence BuchananCDMO, clinical trials, viral vectors, cell and gene therapies, The Biomedical Scientist, vector design, gene therapy, cell therapy, CGT, UK CDMO, Farzin Farzaneh, King's College London, viral vector
ViroCell released in the UK to make viral vectors
ViroCell released in the UK to make viral vectors

ViroCell will supply viral vectors and genetically modified cells to academic and corporate customers for translational cell and gene therapy entering clinical trials.

Read More
In the NewsFlorence BuchananCDMO, clinical trials, viral vectors, cell and gene therapies, EX Bulletin, UK CDMO, gene therapy, cell therapy, CGT, viral vector, vector design, AAV vectors, lentivirus vectors, ViroCell, John W. Hadden II, Farzin Farzaneh, Edmund Truell, Truell Conservation Foundation, King's College London
ViroCell Launched in the UK to Manufacture Viral Vectors
ViroCell Launched in the UK to Manufacture Viral Vectors

ViroCell will supply viral vectors and gene modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials.

Read More
In the NewsFlorence BuchananCDMO, clinical trials, viral vectors, cell and gene therapies, PharmTech.com, gene therapy, cell therapy, AAV vectors, lentivirus vectors, UK CDMO, Farzin Farzaneh, Truell Conservation Foundation, Edmund Truell, King's College London, vector design, CGT